OrthoPediatrics (NASDAQ:KIDS) PT Raised to $42.00

OrthoPediatrics (NASDAQ:KIDS) had its price objective upped by Needham & Company LLC from $37.00 to $42.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price target points to a potential upside of 26.58% from the company’s current price.

Several other research analysts also recently weighed in on the stock. JMP Securities restated a “market outperform” rating and issued a $50.00 target price on shares of OrthoPediatrics in a research note on Tuesday. Truist Financial lowered shares of OrthoPediatrics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $39.00 to $31.00 in a research note on Thursday, January 25th.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $33.18 on Tuesday. The firm’s 50-day simple moving average is $28.91 and its 200 day simple moving average is $29.07. The firm has a market capitalization of $789.35 million, a PE ratio of -36.06 and a beta of 1.16. OrthoPediatrics has a 52 week low of $23.10 and a 52 week high of $48.47. The company has a quick ratio of 2.90, a current ratio of 5.44 and a debt-to-equity ratio of 0.03.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.05. OrthoPediatrics had a negative net margin of 14.10% and a negative return on equity of 5.03%. The company had revenue of $37.61 million during the quarter, compared to the consensus estimate of $37.59 million. On average, equities research analysts predict that OrthoPediatrics will post -1.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Joseph W. Hauser sold 2,903 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $28.06, for a total value of $81,458.18. Following the completion of the sale, the insider now directly owns 52,858 shares in the company, valued at approximately $1,483,195.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, General Counsel Daniel J. Gerritzen sold 2,741 shares of OrthoPediatrics stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $27.59, for a total value of $75,624.19. Following the completion of the transaction, the general counsel now directly owns 52,403 shares of the company’s stock, valued at approximately $1,445,798.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Joseph W. Hauser sold 2,903 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $28.06, for a total transaction of $81,458.18. Following the sale, the insider now owns 52,858 shares in the company, valued at approximately $1,483,195.48. The disclosure for this sale can be found here. Insiders have sold a total of 17,253 shares of company stock valued at $477,375 in the last quarter. Insiders own 31.80% of the company’s stock.

Hedge Funds Weigh In On OrthoPediatrics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Prime Capital Investment Advisors LLC acquired a new position in OrthoPediatrics during the 4th quarter valued at approximately $2,035,000. Vanguard Group Inc. boosted its holdings in shares of OrthoPediatrics by 1.3% during the third quarter. Vanguard Group Inc. now owns 860,804 shares of the company’s stock valued at $27,546,000 after acquiring an additional 10,861 shares during the period. Blue Trust Inc. grew its position in shares of OrthoPediatrics by 1.5% during the fourth quarter. Blue Trust Inc. now owns 28,670 shares of the company’s stock worth $917,000 after acquiring an additional 421 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of OrthoPediatrics by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,731 shares of the company’s stock worth $3,895,000 after acquiring an additional 549 shares during the period. Finally, Conestoga Capital Advisors LLC lifted its position in OrthoPediatrics by 24.0% in the 4th quarter. Conestoga Capital Advisors LLC now owns 45,353 shares of the company’s stock valued at $1,474,000 after purchasing an additional 8,770 shares during the last quarter. 69.05% of the stock is currently owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.